Ifosfamide, Carboplatin, Etoposide, and SGN-30 in Treating Young Patients With Recurrent Anaplastic Large Cell Lymphoma

Inclusion Criteria: Histologically confirmed anaplastic large cell lymphoma CD30-positive disease Must be in first or second relapse Measurable disease No CNS disease Karnofsky performance status (PS) 60-100% (> 16 years of age) OR Lansky PS 60-100% (≤ 16 years of age) Absolute neutrophil count ≥ 1,000/mm³ Platelet count ≥ 100,000/mm³ (transfusion independent) Platelet count ≥ 20,000/mm³ if bone marrow involvement (platelet transfusions allowed) Hemoglobin ≥ 8.0 g/dL (RBC transfusion independent, unless bone marrow involvement) Creatinine adjusted according to age as follows: No greater than 0.4 mg/dL (≤ 5 months) No greater than 0.5 mg/dL (6 months-11 months) No greater than 0.6 mg/dL (1 year-23 months) No greater than 0.8 mg/dL (2 years-5 years) No greater than 1.0 mg/dL (6 years-9 years) No greater than 1.2 mg/dL (10 years-12 years) No greater than 1.4 mg/dL (13 years and over [female]) No greater than 1.5 mg/dL (13 years to 15 years [male]) No greater than 1.7 mg/dL (16 years and over [male]) Creatinine clearance or radioisotope glomerular filtration rate at least 70 mL/min Bilirubin ≤ 1.5 times upper limit of normal (ULN) ALT < 3 times ULN Albumin ≥ 2 g/dL Not pregnant or nursing Negative pregnancy test Fertile patients must use effective contraception during and for ≥ 3 months after completion of study treatment No evidence of graft-vs-host disease No documented active infection requiring antibiotics No isolated bone recurrence Recovered from prior therapy At least 3 months since prior monoclonal antibody therapy At least 3 weeks since prior myelosuppressive chemotherapy (6 weeks for nitrosoureas) At least 7 days since prior hematopoietic growth factor therapy At least 3 months since prior biologic (antineoplastic) agents At least 2 weeks since prior local palliative radiotherapy (small port) At least 3 months since prior total-body irradiation, craniospinal radiotherapy, or radiotherapy to ≥ 50% of the pelvis At least 6 weeks since other prior substantial bone marrow irradiation At least 2 months since prior stem cell transplantation or rescue No prior monoclonal antibody SGN-30 Concurrent steroids allowed provided dose has been stable or decreasing for the past 7 days No concurrent immunosuppressive agents No concurrent dexamethasone as an antiemetic No other concurrent investigational drug or anticancer agents, including chemotherapy, radiotherapy, immunotherapy, or biological therapy